Get more information on Morphine Market - Request Sample Report
The Morphine Market Size was valued at USD 20.03 billion in 2023 and is expected to reach USD 32.81 billion by 2032 and grow at a CAGR of 5.66% over the forecast period 2024-2032.
Increasing incidences of medical conditions characterized by pain and an increasing geriatric population would fuel growth prospects in the morphine market. Morphine is an opiate analgesic, obtained from the opium poppy plant i.e. Papaver somniferum, one of the cornerstones in the treatment of cancer, musculoskeletal disorders, and postoperative pain. According to the Centers for Disease Control and Prevention, in 2020, more than half a billion people around the world were suffering from osteoarthritis, indicating the utmost necessity for proper pain relief treatment. The geriatric population is more susceptible to chronic pain and diseases such as arthritis and comprises the major market for morphine. A study published in May 2021 reveals that over half of the geriatrics suffer from chronic pain. This has naturally increased the consumption of potent painkillers like morphine. Based on a prediction made by the Arthritis Society of Canada, close to 50% of the elderly population more than 65 years of age suffers from arthritis, which will propel the demand for morphine as a prime pain killer.
The WHO also announced in February 2021 that about 1.71 billion people were suffering from musculoskeletal disorders. It is a pretty alarming number that underscores pain management techniques' urgency, and therefore morphine becomes an integral part of the treatment protocols. This is a positive shift in the market due to higher governmental support for opioids in the health sector, particularly in developing markets. Legitimization can spur the ease of availability and acceptance of morphine as a necessary prescription drug. The pharmaceutical company is very heavily investing in the drug as it allows them to expand its use in other new pharmaceutical drugs for a range of diseases including appetite stimulation, resolution of inflammation, and psychiatric conditions.
The morphine market will grow despite the probability of abuse and addiction due to technological improvements in pain management and an increasing focus on palliative care. Even as healthcare professionals continue to develop priorities in effective relief from pain, morphine remains one of the essential drugs in improving the quality of millions suffering from severe pain.
Drivers
Rising Chronic Pain Conditions and Innovations in Drug Delivery Technologies Fuel Demand
The main drivers of the morphine market are the rising prevalence of chronic pain conditions, including cancer, musculoskeletal disorders, and neuropathic pain. The WHO has an estimate about the growing incidence of cancer, almost increasing by 50% in the next two decades, which will require better solutions to manage the pain. This increase in chronic pain disorders has increased the need for effective analgesics like morphine, critical for the relief of severe pain and improvement in the quality of life for these patients.
Advances in drug delivery technologies have also contributed to the growth of the morphine market. The latest and innovative formulations and modes of delivery have enhanced the efficacy and safety of morphine administration. In this respect, a research article published in the Journal of Pain Research in 2022 presents the development of sustained-release patches of morphine which are designed to impart protracted relief from pain and to minimize systemic side effects. Such technological developments ensure not only better adherence on the part of patients but also enhanced clinical outcomes, which can feed into and fuel demand for morphine as a practical pain management option.
All these trends suggest exponential growth in the morphine market as the healthcare community tackles the growing burdens of chronic pain and pushes forward with enhanced drug delivery technologies to enable the patients.
Restraints
The potential side effects of morphine, such as respiratory depression, sedation, and the risk of addiction, pose significant restraints on the market.
The morphine market is significantly impacted by strict regulations imposed by governments and healthcare authorities aimed at reducing the risks of opioid misuse, addiction, and overdose.
by Dosage Form
The injection dosage form of the morphine market dominated the market in 2023, with a huge share of about 70%. Generally, the reason for this dominance is that injections deliver rapid effectiveness for long periods and hence dominate the choices of various healthcare providers treating acute and chronic pain in patients. Contributing to the ever-increasing demand for injectable morphine preparations is the growing incidence of neurological diseases, which are often complicated with significant and chronic pain.
Although the injection segment is market-leading, the oral dosage form is picking up and may most likely be the fastest-growing segment during the forecast period. This can be a result of oral medications being preferred due to easy administration and patient compliance. As healthcare professionals seek the most effective forms of pain management, both injectable and oral morphine has potential uses to fill in the international need for analgesia.
Need any customization research on Morphine Market - Enquiry Now
by Application
In 2023, the biggest application for morphine was pain management with a market share close to 80%. Most applications of morphine directly relate to the treatment of various severe types of pain, such as chronic pain conditions, postoperative pain, and cancer-related pain. The increasingly growing orthopedic disorders and geriatric population who are prone to suffer from chronic pain increase the demand for morphine in the context of pain management.
The cold and cough suppressant segment is expected to be the fastest-growing application through the forecast period. This growth can be accredited to the rising awareness of morphine's efficiency in alleviating severe cough symptoms associated with respiratory infections and other illnesses. As healthcare providers begin to realize that proper symptom management is one of the important aspects of patient care, demand for morphine will most surely increase as an effective treatment for those patients suffering from colds and coughs in their daily lives, showing a transition toward integrated therapeutic use in clinical practice.
The North American morphine market accounted for a huge share of 45.80% in 2023, mainly due to the presence of major players, the huge prevalence of chronic diseases, and a developed healthcare setup. The morphine market in the U.S. will primarily be driven by well-established medical practices and the continuously increasing demand from their client base for pain management solutions. On the other hand, the most rapid growth was reported in Canada, reflecting the growing acceptance of treatments to control pain, as well as government policy promoting opioids as prescription medications within the clinical settings.
The morphine market in the Asia-Pacific is poised to experience immense growth between 2024 and 2032. Some of the factors that drive this growth include the rising prevalence of chronic diseases, such as cardiovascular diseases. Although China will grow the fastest due to its huge population and greater accessibility to advanced medical treatments, it will consume the highest share of the region's market. Besides, the growth in the Indian morphine market is further boosted by rising healthcare costs and heightened awareness of pain treatments both among patients and healthcare providers.
Key Manufacturers of Morphine Drugs
Purdue Pharma
Daiichi Sankyo Inc.
Taj Pharmaceuticals Limited
Sanofi Winthrop Industries
Mayne Pharma Group Limited
Sun Pharmaceutical Industries
Key Suppliers of Raw Morphine
Manus Aktteva Biopharma LLP
Macfarlan Smith
Qinghai Pharmaceutical
Northeast Pharmaceutical Group
Alcaliber
Johnson Matthey Fine Chemicals
Recent Developments
In Aug 2024, The FDA approved the Zurnai (nalmefene injection) auto-injector, designed for the emergency treatment of known or suspected opioid overdoses caused by both natural and synthetic opioids in adults and pediatric patients aged 12 years and older.
In May 2024, Purdue Pharma L.P. entered into an agreement aimed at providing low-cost treatment options for opioid use disorder within correctional facilities. This initiative seeks to address the needs of incarcerated individuals struggling with opioid addiction, thereby enhancing access to essential treatment and supporting efforts to combat the opioid crisis.
| Report Attributes | Details |
|---|---|
| Market Size in 2023 | USD 20.03 Billion |
| Market Size by 2032 | USD 32.81 Billion |
| CAGR | CAGR of 5.66% From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Dosage Form (Injection, Oral, Other Dosage Forms) • By Application (Pain Management, Diarrhea Suppressant, Cold & Cough Suppressant, Others) • By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others) • By End User (Hospitals & Clinics, Ambulatory Surgical Centers, Others) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia-Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia-Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia, Rest of Latin America) |
| Company Profiles | Manus Aktteva Biopharma LLP, Macfarlan Smith, Qinghai Pharmaceutical, Northeast Pharmaceutical Group, Alcaliber, Verve Health Care Ltd., Johnson Matthey Fine Chemicals, and Pfizer Inc. |
| Key Drivers | • Rising Chronic Pain Conditions and Innovations in Drug Delivery Technologies Fuel Demand |
| Restraints | • The potential side effects of morphine, such as respiratory depression, sedation, and the risk of addiction, pose significant restraints on the market. • The morphine market is significantly impacted by strict regulations imposed by governments and healthcare authorities aimed at reducing the risks of opioid misuse, addiction, and overdose. |
Ans: The Morphine market is expected to reach USD 32.81 billion by 2032.
Ans: The Morphine market is grown at a CAGR of 5.66% over the forecast period 2024-2032.
Ans: The forecast period of the Morphine Market is 2024-2032.
Ans: The major players are Manus Aktteva Biopharma LLP, Macfarlan Smith, Qinghai Pharmaceutical, Northeast Pharmaceutical Group, Alcaliber, Verve Health Care Ltd., Johnson Matthey Fine Chemicals, Pfizer Inc, and others in the final report.
Rising Chronic Pain Conditions and Innovations in Drug Delivery Technologies are the key drivers for Morphine Market.
Table of Contents:
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Incidence and Prevalence (2023)
5.2 Prescription Trends, (2023), by Region
5.3 Application Volume: Production and source volumes of pharmaceuticals.
5.4 Healthcare Spending: Expenditure data by government, insurers, and out-of-pocket by patients.
6. Competitive Landscape
6.1 List of Major Companies, by Region
6.2 Market Share Analysis, by Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion plans and new product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Morphine Market Segmentation, by Dosage Form
7.1 Chapter Overview
7.2 Injection
7.2.1 Injection Market Trends Analysis (2020-2032)
7.2.2 Injection Market Size Estimates and Forecasts to 2032 (USD Million)
7.3 Oral
7.3.1 Oral Market Trends Analysis (2020-2032)
7.3.2 Oral Market Size Estimates and Forecasts to 2032 (USD Million)
7.4 Other Dosage Forms
7.4.1 Other Dosage Forms Market Trends Analysis (2020-2032)
7.4.2 Other Dosage Forms Market Size Estimates and Forecasts to 2032 (USD Million)
8. Morphine Market Segmentation, by Application
8.1 Chapter Overview
8.2 Pain Management
8.2.1 Pain Management Market Trends Analysis (2020-2032)
8.2.2 Pain Management Market Size Estimates and Forecasts to 2032 (USD Million)
8.3 Diarrhea Suppressant
8.3.1 Diarrhea Suppressant Market Trends Analysis (2020-2032)
8.3.2 Diarrhea Suppressant Market Size Estimates And Forecasts To 2032 (USD Million)
8.4 Cold & Cough Suppressant
8.4.1 Cold & Cough Suppressant Market Trends Analysis (2020-2032)
8.4.2 Cold & Cough Suppressant Market Size Estimates And Forecasts To 2032 (USD Million)
8.5 Others
8.5.1 Others Market Trends Analysis (2020-2032)
8.5.2 Others Market Size Estimates And Forecasts To 2032 (USD Million)
9. Morphine Market Segmentation, by Distribution Channel
9.1 Chapter Overview
9.2 Hospital Pharmacies
9.2.1 Hospital Pharmacies Market Trends Analysis (2020-2032)
9.2.2 Hospital Pharmacies Market Size Estimates and Forecasts to 2032 (USD Million)
9.3 Retail Pharmacies
9.3.1 Retail Pharmacies Market Trends Analysis (2020-2032)
9.3.2 Retail Pharmacies Market Size Estimates and Forecasts to 2032 (USD Million)
9.4 Online Pharmacies
9.4.1 Online Pharmacies Market Trends Analysis (2020-2032)
9.4.2 Online Pharmacies Market Size Estimates and Forecasts to 2032 (USD Million)
9.5 Others
9.5.1 Others Market Trends Analysis (2020-2032)
9.5.2 Others Market Size Estimates and Forecasts to 2032 (USD Million)
10. Morphine Market Segmentation, by End User
10.1 Chapter Overview
10.2 Hospitals and Clinics
10.2.1 Hospitals and Clinics Market Trends Analysis (2020-2032)
10.2.2 Hospitals and Clinics Market Size Estimates and Forecasts to 2032 (USD Million)
10.3 Ambulatory Surgical Centers
10.3.1 Ambulatory Surgical Centers Market Trends Analysis (2020-2032)
10.3.2 Ambulatory Surgical Centers Market Size Estimates and Forecasts to 2032 (USD Million)
10.4 Others
10.4.1 Others Market Trends Analysis (2020-2032)
10.4.2 Others Market Size Estimates and Forecasts to 2032 (USD Million)
11. Regional Analysis
11.1 Chapter Overview
11.2 North America
11.2.1 Trends Analysis
11.2.2 North America Morphine Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
11.2.3 North America Morphine Market Estimates and Forecasts, by Dosage Form (2020-2032) (USD Million)
11.2.4 North America Morphine Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.2.5 North America Morphine Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
11.2.6 North America Morphine Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
11.2.7 USA
11.2.7.1 USA Morphine Market Estimates and Forecasts, by Dosage Form (2020-2032) (USD Million)
11.2.7.2 USA Morphine Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.2.7.3 USA Morphine Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
11.2.7.4 USA Morphine Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
11.2.8 Canada
11.2.8.1 Canada Morphine Market Estimates and Forecasts, by Dosage Form (2020-2032) (USD Million)
11.2.8.2 Canada Morphine Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.2.8.3 Canada Morphine Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
11.2.8.4 Canada Morphine Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
11.2.9 Mexico
11.2.9.1 Mexico Morphine Market Estimates and Forecasts, by Dosage Form (2020-2032) (USD Million)
11.2.9.2 Mexico Morphine Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.2.9.3 Mexico Morphine Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
11.2.9.4 Mexico Morphine Market Estimates and Forecasts, by End User(2020-2032) (USD Million
11.3 Europe
11.3.1 Eastern Europe
11.3.1.1 Trends Analysis
11.3.1.2 Eastern Europe Morphine Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
11.3.1.3 Eastern Europe Morphine Market Estimates and Forecasts, by Dosage Form (2020-2032) (USD Million)
11.3.1.4 Eastern Europe Morphine Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.3.1.5 Eastern Europe Morphine Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
11.3.1.6 Eastern Europe Morphine Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
11.3.1.7 Poland
11.3.1.7.1 Poland Morphine Market Estimates and Forecasts, by Dosage Form (2020-2032) (USD Million)
11.3.1.7.2 Poland Morphine Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.3.1.7.3 Poland Morphine Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
11.3.1.7.4 Poland Morphine Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
11.3.1.8 Romania
11.3.1.8.1 Romania Morphine Market Estimates and Forecasts, by Dosage Form (2020-2032) (USD Million)
11.3.1.8.2 Romania Morphine Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.3.1.8.3 Romania Morphine Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
11.3.1.8.4 Romania Morphine Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
11.3.1.9 Hungary
11.3.1.9.1 Hungary Morphine Market Estimates and Forecasts, by Dosage Form (2020-2032) (USD Million)
11.3.1.9.2 Hungary Morphine Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.3.1.9.3 Hungary Morphine Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
11.3.1.9.4 Hungary Morphine Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
11.3.1.10 Turkey
11.3.1.10.1 Turkey Morphine Market Estimates and Forecasts, by Dosage Form (2020-2032) (USD Million)
11.3.1.10.2 Turkey Morphine Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.3.1.10.3 Turkey Morphine Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
11.3.1.10.4 Turkey Morphine Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
11.3.1.11 Rest of Eastern Europe
11.3.1.11.1 Rest of Eastern Europe Morphine Market Estimates and Forecasts, by Dosage Form (2020-2032) (USD Million)
11.3.1.11.2 Rest of Eastern Europe Morphine Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.3.1.11.3 Rest of Eastern Europe Morphine Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
11.3.1.11.4 Rest of Eastern Europe Morphine Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
11.3.2 Western Europe
11.3.2.1 Trends Analysis
11.3.2.2 Western Europe Morphine Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
11.3.2.3 Western Europe Morphine Market Estimates and Forecasts, by Dosage Form (2020-2032) (USD Million)
11.3.2.4 Western Europe Morphine Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.3.2.5 Western Europe Morphine Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
11.3.2.6 Western Europe Morphine Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
11.3.2.7 Germany
11.3.2.7.1 Germany Morphine Market Estimates and Forecasts, by Dosage Form (2020-2032) (USD Million)
11.3.2.7.2 Germany Morphine Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.3.2.7.3 Germany Morphine Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
11.3.2.7.4 Germany Morphine Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
11.3.2.8 France
11.3.2.8.1 France Morphine Market Estimates and Forecasts, by Dosage Form (2020-2032) (USD Million)
11.3.2.8.2 France Morphine Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.3.2.8.3 France Morphine Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
11.3.2.8.4 France Morphine Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
11.3.2.9 UK
11.3.2.9.1 UK Morphine Market Estimates and Forecasts, by Dosage Form (2020-2032) (USD Million)
11.3.2.9.2 UK Morphine Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.3.2.9.3 UK Morphine Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
11.3.2.9.4 UK Morphine Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
11.3.2.10 Italy
11.3.2.10.1 Italy Morphine Market Estimates and Forecasts, by Dosage Form (2020-2032) (USD Million)
11.3.2.10.2 Italy Morphine Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.3.2.10.3 Italy Morphine Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
11.3.2.10.4 Italy Morphine Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
11.3.2.11 Spain
11.3.2.11.1 Spain Morphine Market Estimates and Forecasts, by Dosage Form (2020-2032) (USD Million)
11.3.2.11.2 Spain Morphine Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.3.2.11.3 Spain Morphine Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
11.3.2.11.4 Spain Morphine Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
11.3.2.12 Netherlands
11.3.2.12.1 Netherlands Morphine Market Estimates and Forecasts, by Dosage Form (2020-2032) (USD Million)
11.3.2.12.2 Netherlands Morphine Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.3.2.12.3 Netherlands Morphine Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
11.3.2.12.4 Netherlands Morphine Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
11.3.2.13 Switzerland
11.3.2.13.1 Switzerland Morphine Market Estimates and Forecasts, by Dosage Form (2020-2032) (USD Million)
11.3.2.13.2 Switzerland Morphine Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.3.2.13.3 Switzerland Morphine Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
11.3.2.13.4 Switzerland Morphine Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
11.3.2.14 Austria
11.3.2.14.1 Austria Morphine Market Estimates and Forecasts, by Dosage Form (2020-2032) (USD Million)
11.3.2.14.2 Austria Morphine Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.3.2.14.3 Austria Morphine Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
11.3.2.14.4 Austria Morphine Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
11.3.2.15 Rest of Western Europe
11.3.2.15.1 Rest of Western Europe Morphine Market Estimates and Forecasts, by Dosage Form (2020-2032) (USD Million)
11.3.2.15.2 Rest of Western Europe Morphine Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.3.2.15.3 Rest of Western Europe Morphine Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
11.3.2.15.4 Rest of Western Europe Morphine Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
11.4 Asia Pacific
11.4.1 Trends Analysis
11.4.2 Asia Pacific Morphine Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
11.4.3 Asia Pacific Morphine Market Estimates and Forecasts, by Dosage Form (2020-2032) (USD Million)
11.4.4 Asia Pacific Morphine Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.4.5 Asia Pacific Morphine Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
11.4.6 Asia Pacific Morphine Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
11.4.7 China
11.4.7.1 China Morphine Market Estimates and Forecasts, by Dosage Form (2020-2032) (USD Million)
11.4.7.2 China Morphine Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.4.7.3 China Morphine Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
11.4.7.4 China Morphine Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
11.4.8 India
11.4.8.1 India Morphine Market Estimates and Forecasts, by Dosage Form (2020-2032) (USD Million)
11.4.8.2 India Morphine Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.4.8.3 India Morphine Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
11.4.8.4 India Morphine Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
11.4.9 Japan
11.4.9.1 Japan Morphine Market Estimates and Forecasts, by Dosage Form (2020-2032) (USD Million)
11.4.9.2 Japan Morphine Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.4.9.3 Japan Morphine Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
11.4.9.4 Japan Morphine Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
11.4.10 South Korea
11.4.10.1 South Korea Morphine Market Estimates and Forecasts, by Dosage Form (2020-2032) (USD Million)
11.4.10.2 South Korea Morphine Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.4.10.3 South Korea Morphine Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
11.4.10.4 South Korea Morphine Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
11.4.11 Vietnam
11.4.11.1 Vietnam Morphine Market Estimates and Forecasts, by Dosage Form (2020-2032) (USD Million)
11.4.11.2 Vietnam Morphine Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.4.11.3 Vietnam Morphine Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
11.4.11.4 Vietnam Morphine Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
11.4.12 Singapore
11.4.12.1 Singapore Morphine Market Estimates and Forecasts, by Dosage Form (2020-2032) (USD Million)
11.4.12.2 Singapore Morphine Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.4.12.3 Singapore Morphine Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
11.4.12.4 Singapore Morphine Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
11.4.13 Australia
11.4.13.1 Australia Morphine Market Estimates and Forecasts, by Dosage Form (2020-2032) (USD Million)
11.4.13.2 Australia Morphine Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.4.13.3 Australia Morphine Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
11.4.13.4 Australia Morphine Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
11.4.14 Rest of Asia Pacific
11.4.14.1 Rest of Asia Pacific Morphine Market Estimates and Forecasts, by Dosage Form (2020-2032) (USD Million)
11.4.14.2 Rest of Asia Pacific Morphine Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.4.14.3 Rest of Asia Pacific Morphine Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
11.4.14.4 Rest of Asia Pacific Morphine Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
11.5 Middle East and Africa
11.5.1 Middle East
11.5.1.1 Trends Analysis
11.5.1.2 Middle East Morphine Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
11.5.1.3 Middle East Morphine Market Estimates and Forecasts, by Dosage Form (2020-2032) (USD Million)
11.5.1.4 Middle East Morphine Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.5.1.5 Middle East Morphine Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
11.5.1.6 Middle East Morphine Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
11.5.1.7 UAE
11.5.1.7.1 UAE Morphine Market Estimates and Forecasts, by Dosage Form (2020-2032) (USD Million)
11.5.1.7.2 UAE Morphine Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.5.1.7.3 UAE Morphine Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
11.5.1.7.4 UAE Morphine Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
11.5.1.8 Egypt
11.5.1.8.1 Egypt Morphine Market Estimates and Forecasts, by Dosage Form (2020-2032) (USD Million)
11.5.1.8.2 Egypt Morphine Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.5.1.8.3 Egypt Morphine Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
11.5.1.8.4 Egypt Morphine Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
11.5.1.9 Saudi Arabia
11.5.1.9.1 Saudi Arabia Morphine Market Estimates and Forecasts, by Dosage Form (2020-2032) (USD Million)
11.5.1.9.2 Saudi Arabia Morphine Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.5.1.9.3 Saudi Arabia Morphine Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
11.5.1.9.4 Saudi Arabia Morphine Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
11.5.1.10 Qatar
11.5.1.10.1 Qatar Morphine Market Estimates and Forecasts, by Dosage Form (2020-2032) (USD Million)
11.5.1.10.2 Qatar Morphine Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.5.1.10.3 Qatar Morphine Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
11.5.1.10.4 Qatar Morphine Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
11.5.1.11 Rest of Middle East
11.5.1.11.1 Rest of Middle East Morphine Market Estimates and Forecasts, by Dosage Form (2020-2032) (USD Million)
11.5.1.11.2 Rest of Middle East Morphine Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.5.1.11.3 Rest of Middle East Morphine Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
11.5.1.11.4 Rest of Middle East Morphine Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
11.5.2 Africa
11.5.2.1 Trends Analysis
11.5.2.2 Africa Morphine Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
11.5.2.3 Africa Morphine Market Estimates and Forecasts, by Dosage Form (2020-2032) (USD Million)
11.5.2.4 Africa Morphine Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.5.2.5 Africa Morphine Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
11.5.2.6 Africa Morphine Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
11.5.2.7 South Africa
11.5.2.7.1 South Africa Morphine Market Estimates and Forecasts, by Dosage Form (2020-2032) (USD Million)
11.5.2.7.2 South Africa Morphine Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.5.2.7.3 South Africa Morphine Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
11.5.2.7.4 South Africa Morphine Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
11.5.2.8 Nigeria
11.5.2.8.1 Nigeria Morphine Market Estimates and Forecasts, by Dosage Form (2020-2032) (USD Million)
11.5.2.8.2 Nigeria Morphine Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.5.2.8.3 Nigeria Morphine Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
11.5.2.8.4 Nigeria Morphine Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
11.5.2.9 Rest of Africa
11.5.2.9.1 Rest of Africa Morphine Market Estimates and Forecasts, by Dosage Form (2020-2032) (USD Million)
11.5.2.9.2 Rest of Africa Morphine Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.5.2.9.3 Rest of Africa Morphine Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
11.5.2.9.4 Rest of Africa Morphine Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
11.6 Latin America
11.6.1 Trends Analysis
11.6.2 Latin America Morphine Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
11.6.3 Latin America Morphine Market Estimates and Forecasts, by Dosage Form (2020-2032) (USD Million)
11.6.4 Latin America Morphine Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.6.5 Latin America Morphine Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
11.6.6 Latin America Morphine Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
11.6.7 Brazil
11.6.7.1 Brazil Morphine Market Estimates and Forecasts, by Dosage Form (2020-2032) (USD Million)
11.6.7.2 Brazil Morphine Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.6.7.3 Brazil Morphine Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
11.6.7.4 Brazil Morphine Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
11.6.8 Argentina
11.6.8.1 Argentina Morphine Market Estimates and Forecasts, by Dosage Form (2020-2032) (USD Million)
11.6.8.2 Argentina Morphine Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.6.8.3 Argentina Morphine Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
11.6.8.4 Argentina Morphine Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
11.6.9 Colombia
11.6.9.1 Colombia Morphine Market Estimates and Forecasts, by Dosage Form (2020-2032) (USD Million)
11.6.9.2 Colombia Morphine Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.6.9.3 Colombia Morphine Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
11.6.9.4 Colombia Morphine Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
11.6.10 Rest of Latin America
11.6.10.1 Rest of Latin America Morphine Market Estimates and Forecasts, by Dosage Form (2020-2032) (USD Million)
11.6.10.2 Rest of Latin America Morphine Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.6.10.3 Rest of Latin America Morphine Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
11.6.10.4 Rest of Latin America Morphine Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
12. Company Profiles
12.1 Purdue Pharma
12.1.1 Company Overview
12.1.2 Financial
12.1.3 Products/ Services Offered
12.1.4 SWOT Analysis
12.2 Daiichi Sankyo Inc.
12.2.1 Company Overview
12.2.2 Financial
12.2.3 Products/ Services Offered
12.2.4 SWOT Analysis
12.3 Taj Pharmaceuticals Limited
12.3.1 Company Overview
12.3.2 Financial
12.3.3 Products/ Services Offered
12.3.4 SWOT Analysis
12.4 Sanofi Winthrop Industries
12.4.1 Company Overview
12.4.2 Financial
12.4.3 Products/ Services Offered
12.4.4 SWOT Analysis
12.5 Northeast Pharmaceutical Group
12.5.1 Company Overview
12.5.2 Financial
12.5.3 Products/ Services Offered
12.5.4 SWOT Analysis
12.6 Pfizer Inc.
12.6.1 Company Overview
12.6.2 Financial
12.6.3 Products/ Services Offered
12.6.4 SWOT Analysis
12.7 Sun Pharmaceutical Industries
12.7.1 Company Overview
12.7.2 Financial
12.7.3 Products/ Services Offered
12.7.4 SWOT Analysis
12.8 Mallinckrodt Pharmaceuticals
12.8.1 Company Overview
12.8.2 Financial
12.8.3 Products/ Services Offered
12.8.4 SWOT Analysis
12.9 Qinghai Pharmaceutical
12.9.1 Company Overview
12.9.2 Financial
12.9.3 Products/ Services Offered
12.9.4 SWOT Analysis
12.10 Verve Health Care Ltd.
12.10.1 Company Overview
12.10.2 Financial
12.10.3 Products/ Services Offered
12.10.4 SWOT Analysis
13. Use Cases and Best Practices
14. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Key Segmentation
By Dosage Form
Injection
Oral
Other Dosage Forms
By Application
Pain Management
Diarrhea Suppressant
Cold & Cough Suppressant
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
By End User
Hospitals & Clinics
Ambulatory Surgical Centers
Others
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of the Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Product Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Product Matrix which gives a detailed comparison of the product portfolio of each company
Geographic Analysis
Additional countries in any of the regions
Company Information
Detailed analysis and profiling of additional market players (Up to five)
The Pyrogen Testing Market Size was valued at USD 1.60 Billion in 2023 and is expected to reach USD 3.17 Billion by 2032, growing at a CAGR of 7.93% over the forecast period 2024-2032.
The Autoimmune Disease Therapeutics Market size was valued at USD 72.05 billion in 2022 and it is expected to be worth around USD 94.87 billion by 2030 growing at a remarkable CAGR of 3.5% over the forecast period 2023-2030.
The Digital Pathology Market size was estimated at USD 1.05 billion annually by 2023 and is expected to reach USD 1.91 billion by 2031 and improve to a CAGR of 7.8% over the estimated period 2024-2031.
The Cell Reprogramming Market size was valued at US$ 406 million in 2023 and is projected to reach over US$ 725 million by 2031 with an increasing CAGR of 8.53% during the forecast period 2024-2031.
The Molecular Quality Controls Market size was estimated at USD 0.1 billion in 2023 and is expected to reach USD 0.16 billion by 2031 with a growing CAGR of 6.7% during the forecast period of 2024-2031.
The Blood Screening Market size was estimated USD 3.02 billion in 2023 and is expected to reach USD 7.37 billion By 2031 at a CAGR of 11.8% during the forecast period of 2024-2031.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
